Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function

International Journal of Cardiology

Volumn 167, Issue 4, 2013, Pages 1242-1246

  Chu, John W ^a   Jones, Gregory T ^a   Tarr, Gregory P ^a   Vicky Phillips, L ^a   Wilkins, Gerard T ^a   Van Rij, Andre M ^a   Williams, Michael J A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Coronary artery disease; Diastolic function; Extracellular matrix; Matrix metalloproteinase

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CORONARY ARTERY DISEASE; DIASTOLE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE FILLING; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAXATION TIME; RISK ASSESSMENT; VEIN BLOOD FLOW;

CORONARY ARTERY DISEASE; DIASTOLIC FUNCTION; EXTRACELLULAR MATRIX; MATRIX METALLOPROTEINASE;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIASTOLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 84881479585     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.147     Document Type: Article

References (27)

1. W.H. Gaasch, and M.R. Zile Left ventricular diastolic dysfunction and diastolic heart failure Annu Rev Med 55 2004 373 394
2. T.E. Owan, D.O. Hodge, and R.M. Herges Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 2006 251 259
3. F.G. Spinale Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 2007 1285 1342
4. M. Saglam, O. Karakaya, and A.M. Esen Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects Tohoku J Exp Med 208 2006 117 122
5. S.H. Ahmed, L.L. Clark, and W.R. Pennington Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 2006 2089 2096
6. R. Martos, J. Baugh, and M. Ledwidge Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction Circulation 115 2007 888 895
7. P.A. Snoek-van Beurden, and J.W. Von den Hoff Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors Biotechniques 38 2005 73 83
8. R. Hanemaaijer, H. Visser, and Y.T. Konttinen A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels Matrix Biol 17 1998 657 665
9. J.W. Chu, G.T. Jones, and G.P. Tarr Plasma active matrix metalloproteinase 9 associated to diastolic dysfunction in patients with coronary artery disease Int J Cardiol 147 2011 336 338
10. M. Castellazzi, C. Tamborino, and E. Fainardi Effects of anticoagulants on the activity of gelatinases Clin Biochem 40 2007 1272 1276
11. M.A. Quinones, C.M. Otto, and M. Stoddard Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography J Am Soc Echocardiogr 15 2002 167 184
12. R.M. Lang, M. Bierig, and R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
13. S.F. Nagueh, C.P. Appleton, and T.C. Gillebert Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 2009 107 133
14. B.D. Lowes, E.A. Gill, and W.T. Abraham Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure Am J Cardiol 83 1999 1201 1205
15. M. Kasner, D. Westermann, and P. Steendijk Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study Circulation 116 2007 637 647
16. H. Rakowski, C. Appleton, and K.L. Chan Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography J Am Soc Echocardiogr 9 1996 736 760
17. H. Yamada, P.P. Goh, and J.P. Sun Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: clinical application of the Canadian consensus guidelines J Am Soc Echocardiogr 15 2002 1238 1244
18. European Study Group on Diastolic Heart Failure How to diagnose diastolic heart failure Eur Heart J 19 1998 990 1003
19. D. Kelly, G. Cockerill, and L.L. Ng Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study Eur Heart J 28 2007 711 718
20. E.B. Furenes, H. Arnesen, and S. Solheim The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina Thromb Res 124 2009 560 564
21. N. Nishikawa, K. Yamamoto, and Y. Sakata Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation Cardiovasc Res 57 2003 766 774
22. M.H. Tayebjee, S.K. Nadar, R.J. MacFadyen, and G.Y. Lip Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation Am J Hypertens 17 2004 770 774
23. L. Mandinov, F.R. Eberli, C. Seiler, and O.M. Hess Diastolic heart failure Cardiovasc Res 45 2000 813 825
24. M.H. Tayebjee, G.Y. Lip, A.D. Blann, and R.J. Macfadyen Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2 Thromb Res 115 2005 205 210
25. M.H. Tayebjee, G.Y. Lip, and K.T. Tan Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease Am J Cardiol 96 2005 339 345
26. M. Senni, and M.M. Redfield Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 38 2001 1277 1282
27. S. Buralli, F.L. Dini, and P. Ballo Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure Am J Cardiol 105 2010 853 856